Short answer
Solid Biosciences Inc. (SLDB) filed an 8-K current report with the SEC on March 12, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Updated corporate presentation published March 11, 2026 on Solid Biosciences' website.
Solid Biosciences Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation published March 11, 2026 on Solid Biosciences' website
- Reg FD disclosure ensures institutional and retail investors receive simultaneous access to the same strategic update
- Investors should review the presentation directly for pipeline, clinical, or financial guidance updates
Item 8.01 · Other Events
- SGT-003 dosed 40 participants at 1E14vg/kg; Day 360 biopsy data (n=3) shows microdystrophin expression rising to 91% by western blot vs 60% at Day 90
- Key biomarker reductions at Day 90: CK -38%, ALT -43%, LDH -46%, plus 44% reduction in eMHC-positive fibers suggesting disruption of Duchenne's degeneration-regeneration cycle
- Cardiac signal emerging: LVEF stabilization-to-improvement observed, notably in participants with low-normal baseline; meaningful given 59% of Duchenne patients show cardiomyopathy by age 10
- FDA alignment reached on Phase 3 IMPACT DUCHENNE trial design; primary endpoint TTR velocity at 18 months; first participant dosing anticipated Q1 2026
- Accelerated approval pathway discussions with FDA planned H1 2026: outcome could significantly compress commercialization timeline
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Solid Biosciences Inc. 8-K filings
Get the next SLDB 8-K as it lands
Follow SLDB for push alerts, or ask the research agent what this filing means.